Signature Resources Capital Management’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Signature Resources Capital Management’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$6.49K	Buy	+41	New	+$5.54K	﹤0.01%	389

Other funds holding XBI

Larry Mathis Financial Planning Phoenix, Arizona $124B AUM

PSP Research Newtown Square, Pennsylvania $188M AUM

Annex Advisory Services Brookfield, Wisconsin $5.86B AUM 21.83% 1-Year Est. Return

Weatherly Asset Management Del Mar, California $1.4B AUM 36.32% 1-Year Est. Return

Royal Fund Management Lady Lake, Florida $1.2B AUM 32.21% 1-Year Est. Return

New Harbor Financial Group Worcester, Massachusetts $633M AUM 37.53% 1-Year Est. Return

Madrona Financial Services Everett, Washington $543M AUM 30.87% 1-Year Est. Return

L. Roy Papp & Associates Phoenix, Arizona $951M AUM 29.05% 1-Year Est. Return

Sivik Global Healthcare Greenwich, Connecticut $132M AUM 24.1% 1-Year Est. Return

Edge Wealth Management New York $594M AUM 24.92% 1-Year Est. Return

Signature Resources Capital Management's XBI Position: Q2 2026 in Review

Signature Resources Capital Management opened a new position in State Street SPDR S&P Biotech ETF (XBI) in Q2 2026: 41 shares worth $6.49K. The stake represents ﹤0.01% of the portfolio and ranks #389 among its holdings.

260 funds tracked by Wall St. Rank hold XBI as of Q2 2026.

Signature Resources Capital Management held 41 shares of State Street SPDR S&P Biotech ETF worth $6.49K as of Q2 2026.
State Street SPDR S&P Biotech ETF was a new Signature Resources Capital Management position in Q2 2026.
State Street SPDR S&P Biotech ETF made up ﹤0.01% of Signature Resources Capital Management's portfolio in Q2 2026, its #389 holding.
260 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q2 2026.

Based on Signature Resources Capital Management's 13F filing for Q2 2026, filed 14 Jul 2026.